BioSpace News Archive

Drug Development

Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval

While the drug showed significant improvement in patients on a 200mg daily dose of filgotinib, it may not be promoted in the states any time soon.

July 12, 2021
·
2 min read
·
Kate Goodwin
Business

Evidence Building for a Mix and Match Approach to COVID-19 Vaccines

Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.

July 12, 2021
·
5 min read
·
Heather McKenzie
Policy

Experts Push Back on Pfizer Claim That COVID-19 Booster is Necessary Now

HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”

July 12, 2021
·
3 min read
·
Mark Terry
FDA

FDA Gives Enochian Positive Signal on Hijack RNA Treatment for HBV

The company said that it values the FDA’s feedback and is happy that the agency has accepted its request to provide insights on its Hepatitis B development program.

July 12, 2021
·
2 min read
·
Vanessa Doctor, RN
Antacid Market: Rise in Prevalence of Gastroesophageal Reflux Disease (GERD)

The antacid market is expected to reach US$ 11,666.83 million in 2027 from US$ 8,547.97 million in 2019. The market is estimated to grow with a CAGR of 4.0% from 2020-2027.

July 12, 2021
·
3 min read
Policy

In Response to Rare Guillain-Barré Cases, FDA Plans New Warning for J&J COVID-19 Vaccine

Approximately 100 preliminary reports of GBS have been identified out of 12.8 million doses of the J&J vaccine in the U.S., according to the Centers for Disease Control and Prevention.

July 12, 2021
·
3 min read
·
Mark Terry
Business

Biotech IPO Stampede Continues with Five More Companies

The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.

July 12, 2021
·
3 min read
·
Alex Keown
Neoantigens Market: Developments in Neoantigen Vaccines Against Cancer

The neoantigens market was valued at US$ 2,71,428.57 thousand in 2023, and it is projected to reach US$ 10,54,783.54 thousand by 2028; it is expected to grow at a CAGR of 31.2% from 2023 to 2028.

July 12, 2021
·
5 min read
Pharm Country

Navigating Biotech Risks from Discovery to Approval

Up and down the development pipeline, there are vulnerabilities. From shareholder expectations and IP protection to clinical trial risk and cyberattacks, it’s a minefield and enlisting a risk management partner is vital.

July 12, 2021
·
8 min read
·
Heather McKenzie
Policy

Activist Investors Seek to Steer Control of Phoenixus Away from Jailed “Pharma Bro”

A former CEO of Vyera and other activist investors are pushing a slate of new company directors who would steer control of Phoenixus and Vyera away from Shkreli.

July 12, 2021
·
2 min read
·
Alex Keown